Biotechnology company Iksuda Therapeutics has announced positive data from the Phase I study of IKS014 for the treatment of cancer patients with advanced HER2+ solid tumours. 

IKS014, a human epidermal growth factor receptor 2 (HER2)-directed ADC, resulted in anti-tumour activity across all dose levels in various tumour indications. IKS014 was evaluated in a non-randomised, open-label, multicentre trial evaluating the treatment in patients with locally advanced or metastatic solid tumours that express HER2. Data from the trial was presented at the European Society for Medical Oncology (ESMO) Congress in Berlin, Germany. 

At the data cut-off date (31 July 2025), a total of 62 patients were enrolled in the study, with 55 patients evaluable for efficacy as measured by Response Evaluation Criteria in Solid Tumours (RECIST 1.1). Anti-tumour activity was observed across all dose levels, with partial responses and unconfirmed partial responses observed in various tumour indications including breast, lung, oesophageal, ovarian, gastric, gallbladder and gastroesophageal junction cancers and in both HER2+ and HER2-low tumours. 

Amongst 11 participants with breast cancer treated at doses >90mg/m2, seven responses were seen (objective response rate (ORR) 64%), including partial responses in all four patients with HER2+ disease. Three of these patients had previously received Enhertu. Additionally, amongst 10 patients with pre-treated, HER2+ oesophageal cancer that were enrolled across all dose levels, five achieved a response, including complete regression in one patient with non-measurable disease. 

Treatment with IKS014 was generally well-tolerated at doses up to 120mg/m2 (~3.2 mg/kg), with anticipated adverse events including ocular surface AEs, pneumonitis and hypokalaemia, all of which were predominately Grade 1 and Grade 2.  

 “We are hugely encouraged by these data, which illustrates the potential of IKS014 to improve outcomes and address the clinical unmet need across various HER-2 positive cancers, including treatment of those patients which are refractory to prior therapy options,” said Dr Dave Simpson, Chief Executive Officer of Iksuda Therapeutics. 

The results follow positive data from Phase I clinical trials through Fosun Pharma, which is now progressing FS-1502 (IKS014) through Phase III trials in China.  

 

Bruno Quinney, Content Team, DDW